Status:
COMPLETED
Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging
Lead Sponsor:
Pierre Fabre Medicament
Conditions:
Subject
Eligibility:
MALE
18-40 years
Phase:
PHASE1
Brief Summary
The aim of this functional Magnetic Resonance Imaging (MRI) study is to assess the effect of single dose of F2695 at 75mg on modulation of the cerebral motor network.
Eligibility Criteria
Inclusion
- Male right-handed\*, healthy volunteers 18 to 40 years of age. Having signed and dated an informed consent form
Exclusion
- Any significant disease or history of any clinically important drug allergy. Acute disease state within 7 days. History of drug abuse within 1 year. History or current excessive use of alcohol and / or positive alcohol screen. History of narrow angle glaucoma, seizures or epilepsy or brain injury. History of Gluten sensitivity, Gluten intolerance (celiac disease), Wheat allergy or Wheat intolerance.
- History of obstructive voiding symptoms, including urinary retention.
Key Trial Info
Start Date :
April 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT02266966
Start Date
April 1 2014
End Date
September 1 2014
Last Update
October 13 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre d'Investigation Clinique (CIC)
Toulouse, France